Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

Koichi Miyagawa, Josef Rösch, Frank Stanczyk, Kent Hermsmeyer

Research output: Contribution to journalArticlepeer-review

251 Scopus citations


Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17β in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

Original languageEnglish (US)
Pages (from-to)324-327
Number of pages4
JournalNature medicine
Issue number3
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm'. Together they form a unique fingerprint.

Cite this